Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly EBITDA Margin of 4.72% for Q1 2026, up 203007.0% year-over-year from N/an in Q1 2025, and up 98.25% quarter-over-quarter from 269.07% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported EBITDA Margin for 16 consecutive years, with 4.72% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 203007.0% year-over-year to 4.72%; the TTM figure through Mar 2026 stood at 34.79% (up 53377.0% YoY), while the FY2025 annual figure was 98.21%, up 53600.0% from the prior year.
- EBITDA Margin grew to 4.72% in Q1 2026 per LXRX's latest filing, from 269.07% in the prior quarter.
- Across five years, EBITDA Margin topped out at 12.94% in Q2 2025 and bottomed at 68591.43% in Q2 2022.
- Historically, EBITDA Margin has averaged 10321.92% across 5 years, with a median of 3360.9% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 5338868 bps — and 2025, when it plunged 14579 bps.
- Lexicon Pharmaceuticals' EBITDA Margin stood at 68591.43% in 2022, then surged by 91 bps to 6101.44% in 2023, then jumped by 98 bps to 123.28% in 2024, then slumped by 118 bps to 269.07% in 2025, then soared by 98 bps to 4.72% in 2026.
- Business Quant data shows LXRX's EBITDA Margin at 4.72% in Q1 2026, 269.07% in Q4 2025, and 85.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -3,835.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,835.26% |
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -269.07% |
| Sep 30, 2025 | -85.93% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -2,034.79% |
| Dec 31, 2024 | -123.28% |
| Sep 30, 2024 | -3,639.60% |
| Jun 30, 2024 | -3,360.90% |
| Mar 31, 2024 | -4,147.58% |
| Dec 31, 2023 | -6,101.44% |
| Sep 30, 2023 | -30,636.42% |
| Jun 30, 2023 | -15,202.75% |
| Jun 30, 2022 | -68,591.43% |
| Dec 31, 2020 | -3,747.74% |
| Jun 30, 2020 | -258,316.00% |
| Mar 31, 2020 | -780.57% |
| Dec 31, 2019 | -541.05% |
| Sep 30, 2019 | 78.58% |
| Jun 30, 2019 | -2,156.40% |